PERTH-BASED biotechnology company EQiTX has been granted a US patent on its Gingerol technology.
The patents protect a family of compounds and their therapeutic uses for conditions including pain and inflammation.
EQiTX chairman Sol Majteles said the receipt of the patent was a significant milestone for the company.
"This is an exciting project for EQiTX and being granted the US patent consolidates our commercial position in the world’s biggest market," Mr Majteles said.
The announcement follows the recent appointment of Dr Kevin Fahey to the EQiTX Board.
Dr Fahey has held executive research and management positions in the US and was a former senior executive of Pfizer and Biologicals Discovery.